Skip to main content
Erschienen in: American Journal of Clinical Dermatology 2/2023

28.10.2022 | Original Research Article

Patient Care Outcomes in Hospitalized Patients with Acute Generalized Exanthematous Pustulosis: A Cross-Sectional Database Study

verfasst von: Kelsey B. Nusbaum, Trent D. Walker, Sonia Himed, John Christopher Trinidad, Natalie Spaccarelli, Catherine Chung, Benjamin H. Kaffenberger

Erschienen in: American Journal of Clinical Dermatology | Ausgabe 2/2023

Einloggen, um Zugang zu erhalten

Abstract

Background

Current understanding of the etiology, natural history, and outcomes of acute generalized exanthematous pustulosis (AGEP) has been limited, with most available studies consisting of small or heterogenous cohorts.

Objectives

The aim of this study was to further characterize associated factors and disease outcomes of AGEP.

Methods

A cross-sectional study design was employed with formal inclusion and causality criteria. Patients were identified from an inpatient database at an academic medical center, including 65 patients with AGEP and a control group of 61 patients with non-severe cutaneous adverse reactions.

Results

Increased age and body mass index (BMI) were associated with higher risk of AGEP (p < 0.001). Length of stay was longer for both the overall AGEP cohort (13.1 days) and a subcohort with a primary discharge diagnosis of AGEP (9.7 days) compared with the control group (3.6 days) [p < 0.001]. Patients with AGEP were more likely to be discharged to a long-term care facility compared with control patients (p < 0.001).

Conclusions

AGEP was associated with longer length of hospitalization, higher rates of discharge to long-term care facilities, and higher mortality compared with non-severe cutaneous adverse drug reaction (SCAR) medication reactions. Future research should examine the association between morbid obesity and this particular drug reaction, and the possibility of decreasing hospitalization length given the relatively low risk of mortality among patients with AGEP.
Literatur
1.
Zurück zum Zitat Sidoroff A, Halevy S, Bavinck JNB, et al. Acute generalized exanthematous pustulosis (AGEP)—a clinical reaction pattern. J Cutan Pathol. 2001;28:113–9.CrossRefPubMed Sidoroff A, Halevy S, Bavinck JNB, et al. Acute generalized exanthematous pustulosis (AGEP)—a clinical reaction pattern. J Cutan Pathol. 2001;28:113–9.CrossRefPubMed
2.
Zurück zum Zitat Szatkowski J, Schwartz RA. Acute generalized exanthematous pustulosis (AGEP): a review and update. J Am Acad Dermatol. 2015;73:843–8.CrossRefPubMed Szatkowski J, Schwartz RA. Acute generalized exanthematous pustulosis (AGEP): a review and update. J Am Acad Dermatol. 2015;73:843–8.CrossRefPubMed
3.
Zurück zum Zitat Oh DAQ, Yeo YW, Choo KJL, et al. Acute generalized exanthematous pustulosis: Epidemiology, clinical course, and treatment outcomes of patients treated in an Asian academic medical center. JAAD Int. 2021;3:1–6.CrossRefPubMedPubMedCentral Oh DAQ, Yeo YW, Choo KJL, et al. Acute generalized exanthematous pustulosis: Epidemiology, clinical course, and treatment outcomes of patients treated in an Asian academic medical center. JAAD Int. 2021;3:1–6.CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Sidoroff A, Dunant A, Viboud C, et al. Risk factors for acute generalized exanthematous pustulosis (AGEP)—results of a multinational case-control study (EuroSCAR). Br J Dermatol. 2007;157:989–96.CrossRefPubMed Sidoroff A, Dunant A, Viboud C, et al. Risk factors for acute generalized exanthematous pustulosis (AGEP)—results of a multinational case-control study (EuroSCAR). Br J Dermatol. 2007;157:989–96.CrossRefPubMed
5.
Zurück zum Zitat Thienvibul C, Vachiramon V, Chanprapaph K. Five-year retrospective review of acute generalized exanthematous pustulosis. Dermatol Res Pract. 2015;2015: 260928.CrossRefPubMedPubMedCentral Thienvibul C, Vachiramon V, Chanprapaph K. Five-year retrospective review of acute generalized exanthematous pustulosis. Dermatol Res Pract. 2015;2015: 260928.CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Bhat YJ, Akhtar S, Ahmad M, et al. Etiopathological and clinical study of acute generalized exanthematous pustulosis: experience from a tertiary care hospital in North India. Indian Dermatol Online J. 2020;11:391.CrossRefPubMedPubMedCentral Bhat YJ, Akhtar S, Ahmad M, et al. Etiopathological and clinical study of acute generalized exanthematous pustulosis: experience from a tertiary care hospital in North India. Indian Dermatol Online J. 2020;11:391.CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Loo C, Tan W, Khor Y, et al. A 10-year retrospective study on severe cutaneous adverse reactions (SCARs) in a tertiary hospital in Penang Malaysia. Med J Malaysia. 2018;73:73–7.PubMed Loo C, Tan W, Khor Y, et al. A 10-year retrospective study on severe cutaneous adverse reactions (SCARs) in a tertiary hospital in Penang Malaysia. Med J Malaysia. 2018;73:73–7.PubMed
8.
Zurück zum Zitat Hadavand MA, Kaffenberger B, Cartron AM, et al. Clinical presentation and management of atypical and recalcitrant acute generalized exanthematous pustulosis (AGEP). J Am Acad Dermatol. 2020;87(3):632–9.CrossRefPubMed Hadavand MA, Kaffenberger B, Cartron AM, et al. Clinical presentation and management of atypical and recalcitrant acute generalized exanthematous pustulosis (AGEP). J Am Acad Dermatol. 2020;87(3):632–9.CrossRefPubMed
9.
Zurück zum Zitat Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239–45.CrossRefPubMed Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239–45.CrossRefPubMed
10.
Zurück zum Zitat Goldenberg M, Amigo M, Krishna S, et al. Validation of generalized drug-related rash diagnoses using International Classification of Diseases 9th and 10th revision codes. Br J Dermatol. 2022;186(3):583–5.CrossRefPubMed Goldenberg M, Amigo M, Krishna S, et al. Validation of generalized drug-related rash diagnoses using International Classification of Diseases 9th and 10th revision codes. Br J Dermatol. 2022;186(3):583–5.CrossRefPubMed
11.
Zurück zum Zitat Yoshikawa TT, Norman DC. Geriatric infectious diseases: current concepts on diagnosis and management. J Am Geriatr Soc. 2017;65:631–41.CrossRefPubMed Yoshikawa TT, Norman DC. Geriatric infectious diseases: current concepts on diagnosis and management. J Am Geriatr Soc. 2017;65:631–41.CrossRefPubMed
12.
13.
Zurück zum Zitat Zarb P, Amadeo B, Muller A, et al. Antimicrobial prescribing in hospitalized adults stratified by age. Drugs Aging. 2012;29:53–62.CrossRefPubMed Zarb P, Amadeo B, Muller A, et al. Antimicrobial prescribing in hospitalized adults stratified by age. Drugs Aging. 2012;29:53–62.CrossRefPubMed
14.
Zurück zum Zitat Pea F. Pharmacokinetics and drug metabolism of antibiotics in the elderly. Expert Opin Drug Metab Toxicol. 2018;14:1087–100.CrossRefPubMed Pea F. Pharmacokinetics and drug metabolism of antibiotics in the elderly. Expert Opin Drug Metab Toxicol. 2018;14:1087–100.CrossRefPubMed
15.
Zurück zum Zitat Cojutti P, Arnoldo L, Cattani G, et al. Polytherapy and the risk of potentially inappropriate prescriptions (PIPs) among elderly and very elderly patients in three different settings (hospital, community, long-term care facilities) of the Friuli Venezia Giulia region, Italy: are the very elderly at higher risk of PIPs? Pharmacoepidemiol Drug Saf. 2016;25:1070–8.CrossRefPubMed Cojutti P, Arnoldo L, Cattani G, et al. Polytherapy and the risk of potentially inappropriate prescriptions (PIPs) among elderly and very elderly patients in three different settings (hospital, community, long-term care facilities) of the Friuli Venezia Giulia region, Italy: are the very elderly at higher risk of PIPs? Pharmacoepidemiol Drug Saf. 2016;25:1070–8.CrossRefPubMed
16.
Zurück zum Zitat Modesto ACF, Silveira EA, Rodrigues APDS, et al. Prevalence of adverse drug events in severely obese adults and associated factors: clinical trial baseline results. Sci Pharm. 2020;88:41.CrossRef Modesto ACF, Silveira EA, Rodrigues APDS, et al. Prevalence of adverse drug events in severely obese adults and associated factors: clinical trial baseline results. Sci Pharm. 2020;88:41.CrossRef
18.
Zurück zum Zitat Bremmer S, Van Voorhees AS, Hsu S, et al. Obesity and psoriasis: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2010;63:1058–69.CrossRefPubMed Bremmer S, Van Voorhees AS, Hsu S, et al. Obesity and psoriasis: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2010;63:1058–69.CrossRefPubMed
19.
Zurück zum Zitat Yosipovitch G, DeVore A, Dawn A. Obesity and the skin: skin physiology and skin manifestations of obesity. J Am Acad Dermatol. 2007;56:901–16.CrossRefPubMed Yosipovitch G, DeVore A, Dawn A. Obesity and the skin: skin physiology and skin manifestations of obesity. J Am Acad Dermatol. 2007;56:901–16.CrossRefPubMed
Metadaten
Titel
Patient Care Outcomes in Hospitalized Patients with Acute Generalized Exanthematous Pustulosis: A Cross-Sectional Database Study
verfasst von
Kelsey B. Nusbaum
Trent D. Walker
Sonia Himed
John Christopher Trinidad
Natalie Spaccarelli
Catherine Chung
Benjamin H. Kaffenberger
Publikationsdatum
28.10.2022
Verlag
Springer International Publishing
Erschienen in
American Journal of Clinical Dermatology / Ausgabe 2/2023
Print ISSN: 1175-0561
Elektronische ISSN: 1179-1888
DOI
https://doi.org/10.1007/s40257-022-00737-5

Weitere Artikel der Ausgabe 2/2023

American Journal of Clinical Dermatology 2/2023 Zur Ausgabe

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Studienlage spricht für Isotretinoin zur Rosazea-Therapie

23.05.2024 Rosazea Nachrichten

Isotretinoin wird off-label zur Behandlung von Rosazea eingesetzt. Wie solide die Evidenz dafür ist, wurde jetzt in einem systematischen Review überprüft.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Riesenzellarteriitis: 15% der Patienten sind von okkulter Form betroffen

16.05.2024 Riesenzellarteriitis Nachrichten

In einer retrospektiven Untersuchung haben Forschende aus Belgien und den Niederlanden die okkulte Form der Riesenzellarteriitis genauer unter die Lupe genommen. In puncto Therapie und Rezidivraten stellten sie keinen sehr großen Unterschied zu Erkrankten mit kranialen Symptomen fest.

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.